Molecular Partners AG(US:MOLN) Globenewswireยท2025-11-12 06:00Core Insights - Molecular Partners AG presented new data on MP0712, a Radio-DARPin targeting DLL3, at the Targeted Radiopharmaceuticals Summit Europe, showcasing promising human imaging results and supporting mechanism of action data [1][2][3] Group 1: Clinical Development - MP0712 is being developed in collaboration with Orano Med for treating small cell lung cancer (SCLC) and other neuroendocrine cancers [1][2] - The Phase 1 Investigational New Drug (IND) application for MP0712 has been filed, with the trial expected to start by the end of 2025, pending regulatory clearance [7][8] - Initial clinical data from the Phase 1/2a study is anticipated in 2026 [7][8] Group 2: Imaging and Mechanism of Action - The imaging data indicates targeted delivery of MP0712 into tumors with minimal exposure to healthy organs, suggesting its potential effectiveness in a clinical setting [2][3] - A case study showed specific uptake of Pb-MP0712 in tumor lesions at 24 hours, sustained over 4 days, with limited accumulation in healthy organs [3][5] - MP0712 is engineered for half-life optimization to maintain sufficient drug levels in the blood, supporting its intended mechanism of action [3][6] Group 3: Technology and Innovation - The Radio-DARPin platform combines the targeting capabilities of DARPins with the therapeutic potential of lead isotopes, aiming to improve delivery of radioactive payloads to tumors [11][12] - DARPins offer advantages in drug design, including high specificity, small size, and stability, which can enhance therapeutic efficacy [12][13]